EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Cytoreductive nephrectomy in the era of immune‐checkpoint inhibitors: back to the future?

Rocco Simone Flammia iD, Riccardo Campi iD, Eugenio Bologna, Riccardo Bertolo, Costantino Leonardo, Fabio Calabrò, Daniele Amparore, Giuseppe Simone, Young Academic Urologists (YAU) Renal Cancer Working Group

BJU International · 2026

DOI: 10.1111/bju.70168 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift BJU International, 2026. Verfasst von Rocco Simone Flammia und 8 weiteren Autor:innen. Beteiligte Einrichtung: Uro-Oncology Program, IRCCS Regina Elena National Cancer Institute, Rome, Italy. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Cytoreduction Surgical Procedures, Immune Checkpoint Inhibitors, Kidney Neoplasms. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To investigate the role of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC) treated with immune‐checkpoint inhibitors (ICIs).

Methods

A narrative review was carried out using PubMed and searching for English articles published from January 2015 to May 2025.

Results

After the screening process, 12 retrospective studies comparing outcomes in patients with mRCC treated with ICI‐based regimens, with or without CN (either upfront or deferred) were deemed eligible. Of those, six indicated a survival benefit for patients undergoing CN in combination with ICIs with hazards ratios ranging from 0.19 to 0.63, a finding that remains consistent within the upfront CN subgroup. However, the included studies’ retrospective nature, inherent selection, and immortal time biases limit definitive conclusions. Ongoing phase III randomised trials, NORDIC‐SUN (ClinicalTrials.gov identifier: NCT03977571) and Southwest Oncology Group (SWOG)‐1931 (also known as PROBE; NCT04510597 ), are evaluating the role of deferred CN after initial ICI therapy, while the role of upfront CN in the ICI era will be likely elucidated by SEVURO‐CN (NCT05753839) trial.

Conclusion

Our findings highlight reconsidering the importance of CN in the ICI era, potentially driven by the influence of tumour burden on anti‐cancer immunity and the limited efficacy of ICIs against primary tumours. Future research, ideally through randomised trials involving patients suitable for safe surgery, should aim to clarify the optimal timing of CN in the context of ICI therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellCytoreduction Surgical ProceduresImmune Checkpoint InhibitorsKidney NeoplasmsNephrectomyHumansClinical Trials, Phase III as Topic

Stichwörter der Autor:innen

cytoreductive nephrectomyimmune‐checkpointimmunotherapyrenal neoplasmtyrosine kinase inhibitor

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Uro-Oncology Program, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Advanced Surgical Technologies PhD programme, Sapienza University of Rome, Rome, Italy.
  • Urological Robotic Surgery and Renal Transplantation Unit, Department of Experimental and Clinical Medicine Careggi Hospital, University of Florence, Florence, Italy.
  • European Association of Urology (EAU), Young Academic Urologists (YAU) Renal Cancer Working Group, Arnhem, The Netherlands.
  • Urology Unit, Department of Surgery, Dentistry, Pediatrics and Gynecology, University of Verona - Azienda Ospedaliera Universitaria Integrata Verona (AOUI), Verona, Italy.
  • Division of Urology, Department of Surgery, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy.

ORCID-Profile: Rocco Simone Flammia, Riccardo Campi

Zitieren

APA

Flammia, R. S., Campi, R., Bologna, E., Bertolo, R., Leonardo, C., Calabrò, F., Amparore, D., Simone, G., & Young Academic Urologists (YAU) Renal Cancer Working Group (2026). Cytoreductive nephrectomy in the era of immune‐checkpoint inhibitors: back to the future?. BJU International. https://doi.org/10.1111/bju.70168

Vancouver

Flammia RS, Campi R, Bologna E, Bertolo R, Leonardo C, Calabrò F, et al. Cytoreductive nephrectomy in the era of immune‐checkpoint inhibitors: back to the future?. BJU International. 2026. doi:10.1111/bju.70168

BibTeX
@article{Flammia2026,
  author = {Flammia, Rocco Simone and Campi, Riccardo and Bologna, Eugenio and Bertolo, Riccardo and Leonardo, Costantino and Calabrò, Fabio and Amparore, Daniele and Simone, Giuseppe and Young Academic Urologists (YAU) Renal Cancer Working Group, Young Academic Urologists (YAU) Renal Cancer Working Group},
  title = {Cytoreductive nephrectomy in the era of immune‐checkpoint inhibitors: back to the future?},
  journal = {BJU International},
  year = {2026},
  doi = {10.1111/bju.70168}
}
Kostenlos starten →